Obesity does not affect #SLE disease activity despite persistent ⬆️in CRP. From Toronto #lupus database #ACR21 abst#0864 @RheumNow https://t.co/4ZpAMaU0jk

Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21 👉🏼~1000 pts 👉🏼Severe outcomes esp in #GCA and #AAV 👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes @RheumNow https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL

• Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and…

Dr Jin @SeoyoungCKim population-based study on predictors of switching after 1st line TNFi use. 22% switch, most to 2nd TNFi.👩, prior steroid use predicted change, other autoimmune disease and vit D use negative predictors. Abstr#579 #ACR21 @RheumNow https://t.co/YpZ5rGBiod

‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7

2 year extension study on Upadacitinib in active AS ⭐️ASAS40 response maintained ⭐️MRI SPARCC scores decreased and maintained ⭐️infections most common AE ⭐️NO MACE, lymphoma, skin cancer, GI perforations Abs#924 #ACR21 #ACRBest @RheumNow https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ

• Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondyli…

Jorge Plutzky, cardiologist perspective on RA at #ACR21 ⭐️CANTOS: Canakinumab for MACE shows ⬇️ inflammation, no change in LDL. Improvement in MACE events ▶️Plutzky: "Proof of concept study" @Rheumnow https://t.co/Xi9ZHxMtmu

Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very important given the harm of opioids Abstr#587 #ACR21 @RheumNow https://t.co/d1Dharf5jZ

We need to control not only inflammation but also lipids levels in our patients w/ IA! Dr Plutzky brilliantly talking us through CV risk and RA showing data on how poor LDL control and coronary microvascular dysfunction lead to worse long term CV outcomes. @RheumNow #ACR21 https://t.co/o6GWHDai5z

@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw

Attaining low disease activity in #SLE ⬇️ mortality! More time in LLDAS = #lupus low disease activity state = ⬆️survival in >4000 pts with SLE. Also + was clinical remission on treatment CROT. Treat to a target has come to SLE @RheumNow #ACR21 abst0865 #ACRBest #RheumPix https://t.co/8ld8oncFRR

The drug retention for SEC and TNFi was similar in this RW study of 279 patients (TNFi 178, SEC 101).In subgroups analyses, age, BASDAI at diagnosis and BMI did not favour any group @RheumNow #ACR21 Abst#0911 https://t.co/g1tIy1qMX1 https://t.co/LHZMxMlzIB

• Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondylo…

Dr. P Crow #PhilipHench provides a tour of research on SLE pathogenesis: 👉discovery of Ab to small nuclear RNAs and the spliceosome 👉T cells' role on B cell differentiation 👉⬆️CD40L on SLE lymphocytes 👉IFN genes and their effects on the immune system #ACR21 @rheumnow https://t.co/6v9O19UUxX

No significant difference in effectiveness/treatment survival of different TNFi in axSpA Failure of 1st TNFi did not diminish effectiveness of a second TNFi Abs#938 #ACR21 @RheumNow https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6

• Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors fo…

#ACR21 #Abstr0686 A study used PET-CT to initially rule out cancer. Interestingly, they found ⬆️median muscle FDG uptake with PET-CT in IIM vs Non-IIM. Need further study on its added value compared to MRI/EMG @RheumNow https://t.co/F0B86ygjI9 https://t.co/eiJnqpU8ft

• Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in …